RxDoctor Payments Data

Laurie Tompkins, APRN

Women's Health · Brentwood, TNNPI 1639266745

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $16,658 of the $27,073 with a category attached, or 61.5%. 28 manufacturers reported payments, led by Myovant Sciences Inc. at 34.0% of the total. Reporting peaked in 2022 at $16,946 and has fallen 97.4% since, to $444 in 2025. Among women's health clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,073in general payments, 2019–2025

Across 257 payments — averaging $105.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myovant Sciences Inc.$9K
  • AbbVie$5K
  • Astellas Pharma US Inc$4K
  • Sumitomo Pharma America, Inc.$4K
  • Pfizer$4K
  • Exeltis, USA Inc.$284
  • plus $2K from 22 others

What the payments were for

  • Consulting fees$2,70010%
  • Speaking & faculty fees$16,65862%
  • Travel & lodging$3,14912%
  • Food & beverage$4,25016%
  • Education$3161%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,073 in reported general payments places this provider in the 95th percentile of 202 women's health providers in Tennessee.

See all women's health providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,661
Medicare patients
17
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron11$10,668
PremarinEstrogens, Conjugated15$7,372
Estradiol (Twice Weekly)Estradiol48$4,519
Estradiol51$2,388
ProgesteroneProgesterone, Micronized46$1,669
Sertraline Hcl12$120
Fluconazole11$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$4,153$10,66811 claims
PfizerPremarin$3,541$7,37215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 202 women's health providers in Tennessee.

Other women's health in Brentwood

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →